Report on the EGA's Legal Affairs Forum which took place in Brussels on 17-18 March 2011
Yasmin® is an oral contraceptive pill containing two steroidal hormones, ethinylestradiol and drospirenone. It is marketed by Bayer Schering Pharma AG (“Bayer”) for the prevention of pregnancy in women. Yasmin® is one of a number of birth-control products of Bayer, which together recorded worldwide sales of approximately $1.56 billion in 2010.
An obviousness case in the English Patents Court concerning a patent on an ophthalmic combination product.
A failed obviousness case on an enantiomer patent - and an interesting SPC decision too.
Report on the Pfizer v Teva UK battle over atorvastatin
Court of Justice rules on the eligibility of old drug products for SPCs
The European Commission has published its latest report on patent settlement agreements in the pharma sector.
Ranbaxy avoids AstraZeneca’s purity patent to take first mover advantage on esomeprazole in the UK.
